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Abstract 
Background: Composite pheochromocytoma is a rare pathological condition characterized by elements of both 
pheochromocytoma and neurogenic tumors. However, detailed clinical outcomes of this tumor have not been fully 
shown. From 2007 to 2013, we experienced three cases of adrenal composite pheochromocytoma. In this report, 
we investigate the clinicopathological features of these three cases of composite pheochromocytoma and compare 
them with previously reported cases.
Case presentations: Cases 1 and 2 were a 29-year-old Japanese woman and a 59-year-old Japanese man, respec-
tively. They underwent laparoscopic left adrenalectomy, and pathological examination revealed composite pheo-
chromocytoma–ganglioneuroma. Case 3 was a 53-year-old Japanese man who had been receiving hemodialysis for 
17 years. He underwent laparoscopic right adrenalectomy, and pathological examination revealed composite pheo-
chromocytoma–ganglioneuroblastoma. Although the Ki67-positive rates varied from 1.0 to 6.2% among the three 
cases, no clinical recurrences occurred. Despite the relatively high rate of Ki67 positivity, complete tumor resection 
resulted in favorable clinical outcomes.
Conclusion: We experienced three cases of adrenal composite pheochromocytoma. Although the clinical findings 
and treatment outcomes of composite pheochromocytoma were similar to those of ordinary pheochromocytoma, 
further studies of the biological behavior and genetic profiles of composite pheochromocytoma are necessary to 
achieve a better understanding of this tumor.
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Background
Ordinary pheochromocytoma is a neuroendocrine tumor 
derived from the adrenal medulla. It consists of polygonal 
and spindle cells arranged in alveolar, trabecular, or solid 
patterns and often exhibits a typical Zellballen pattern. 
Composite pheochromocytoma is a rare tumor composed 
histologically of pheochromocytoma and other neurogenic 
tumor components such as neuroblastoma, ganglioneuro-
blastoma, ganglioneuroma, peripheral nerve sheath tumor, 
or other types of neuroendocrine carcinoma [1]. The fre-
quency of composite adrenal tumors reportedly ranges 
from <3% of all adrenal gland neoplasms to 1–9% of pheo-
chromocytomas. Composite pheochromocytoma is rela-
tively rare among composite adrenal tumors, accounting 
for only 3% of pheochromocytomas [1, 2]. We experienced 
three cases of adrenal composite pheochromocytoma 
from 2007 to 2013 (Table 1). Two of these were compound 
tumors comprising pheochromocytoma and ganglioneu-
roma, and the other was a tumor comprising pheochro-
mocytoma and ganglioneuroblastoma. We herein report 




A 29-year-old Japanese woman presented with parox-
ysmal palpitation and headache. She had no history of 
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hypertension. Blood catecholamine analysis during the 
palpitation revealed epinephrine, norepinephrine, and 
dopamine levels of 417 pg/ml (reference range, 0–100 pg/
ml), 2,665  pg/ml (reference range, 100–450  pg/ml), 
and 16  pg/ml (reference range, 0–60  pg/ml), respec-
tively. Magnetic resonance imaging revealed a hetero-
geneous left adrenal mass with slightly high intensity on 
T2-weighted images (Figure  1a). 123I-meta-iodobenzyl-
guanidine (MIBG) scintigraphy showed a high level of 
accumulation in the left adrenal tumor. After diagnosis of 
left adrenal pheochromocytoma, the patient underwent 
laparoscopic left adrenalectomy. Pathological findings 
showed a composite pheochromocytoma-ganglioneu-
roma in which 4.3% of cells were Ki67-positive (Figure 2a, 
d, g). She was followed closely after surgery. Despite the 
high number of Ki67-positive cells, no recurrence was 
observed for 2 years.
Case 2
A 59-year-old Japanese man presented with asymp-
tomatic macrohematuria. He had a history of angina 
pectoris and took a daily dose of aspirin. Abdominal 
ultrasonography showed no evidence of a renal or blad-
der tumor, and cystoscopy showed no evidence of a blad-
der tumor. Computed tomography revealed a 5.5-cm left 
adrenal mass  (Figure  1b). Blood catecholamine analysis 
revealed epinephrine, norepinephrine, and dopamine 
levels of 136  pg/ml (reference range, 0–100  pg/ml), 
458 pg/ml (reference range, 100–450 pg/ml), and 15 pg/
ml (reference range, 0–60 pg/ml), respectively. 123I-MIBG 
scintigraphy showed a high level of accumulation in the 
left adrenal gland. After diagnosis of a left adrenal phe-
ochromocytoma, the patient underwent laparoscopic 
left adrenalectomy. Pathological examination revealed a 
composite pheochromocytoma–ganglioneuroma with 
focal Ki67-positive cells (1%) (Figure 2b, e, h).
Case 3
A 53-year-old Japanese man presented with asympto-
matic macrohematuria. He had undergone hemodialysis 
for 17 years and had a history of hypertension. Cystos-
copy showed no evidence of a bladder tumor. Abdominal 
Table 1 Clinicopathological findings of three composite pheochromocytomas
a Five areas of greater Ki67 expression intensity (hot spots) were selected. At least 500 cells were counted, and the ratio between the number of cells with a positively 
stained nucleus and the total number of cells was calculated.
Case Sex Clinical manifestation Tumor size (cm) Morphologic feature Ki67 indexa (%)
1 F/29 Palpitation 4.5 Ganglioneuroma 4.3
2 M/59 Asymptomatic hematuria 5.5 Ganglioneuroma 1.0







Figure 1 Computed tomography or magnetic resonance imaging 
of three composite pheochromocytomas. a Magnetic resonance 
imaging revealing a heterogeneous left adrenal mass (indicated by 
arrowhead) with slightly high intensity on T2-weighted images. b 
Computed tomography scan showing a left adrenal mass (indicated 
by arrowhead). c Magnetic resonance imaging showing acquired 
cystic kidney disease and a right adrenal mass (indicated by arrow-
head).
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magnetic resonance imaging showed acquired cystic 
kidney disease and a 3-cm right adrenal mass  (Fig-
ure 1c). Serum catecholamine analysis revealed an epi-
nephrine level of 50 pg/ml (reference range, 0–100 pg/
ml), norepinephrine level of 3,801  pg/ml (reference 
range, 100–450 pg/ml), and dopamine level of 90 pg/ml 
(reference range, 0–60  pg/ml). 123I-MIBG scintigraphy 
revealed strong accumulation in the right adrenal gland. 
After diagnosis of a right adrenal pheochromocytoma, 
the patient underwent laparoscopic right adrenalec-
tomy. Pathological examination revealed a composite 
pheochromocytoma–ganglioneuroblastoma with a 6.2% 
rate of Ki67-positive cells  (Figure  2c, f, i). Despite the 
unfavorable tumor histology, he remained tumor-free 
for 6 years after the surgery.
In the present report, two patients showed asymp-
tomatic hematuria. However, cystoscopy showed no 
evidence of a bladder tumor. The ratio of eventual coex-
istence of hematuria and composite pheochromocytoma 
was unknown, although we reviewed previous reports.
Discussion
Tumors derived from the adrenal medulla are classified 
as either pheochromocytomas or neuroblastic tumors. 
Composite pheochromocytoma is a rare pathological 
entity that is composed of pheochromocytoma and other 
histological components, most frequently neuroblastic 
elements. Neuroblastic tumors such as neuroblastoma, 
ganglioneuroblastoma, and ganglioneuroma are tumors 



















Figure 2 Microscopic findings of resected tumors. Left lanes (a–c) pheochromocytoma component (hematoxylin and eosin staining, ×400). Middle 
lanes (d–f) ganglioneuroma or ganglioneuroblastoma components. d, e Ganglioneuroma component (hematoxylin and eosin staining, ×400). 
f Ganglioneuroblastoma component (Nissl staining, ×400). Right lanes (g–i) positive immunohistochemical staining of the pheochromocytoma 
component with Ki67 (×200).
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primitive sympathogonia. They are usually observed in 
the neck, posterior mediastinum, adrenal gland, retrop-
eritoneum, and pelvis [3]. The diagnosis of a composite 
tumor is currently based only on the histopathological 
findings. Shawa et  al. [4] reported that pheochromo-
cytoma–ganglioneuroma composites are clinically and 
radiologically indistinguishable from pheochromocyto-
mas and need to be managed similarly.
Pheochromocytoma was often termed “the 10% tumor” 
at the end of the 20th century. However, pheochromo-
cytoma is not described this way any longer. Until 2002, 
10% of all pheochromocytomas were considered to be 
hereditary. However, among 271 patients who presented 
with nonsyndromic pheochromocytoma and without 
a family history of the disease, 66 (24%) were found to 
have a hereditary predisposition [5]. In another study, 
Amar et  al. [6] reported that 86 (27.4%) of 314 patients 
had a hereditary pheochromocytoma or functional 
paraganglioma.
Several genes are known to play an important role in 
the pathogenesis of pheochromocytoma, including the 
RET proto-oncogene, von Hippel–Lindau disease tumor 
suppressor (VHL), neurofibromatosis type 1 tumor 
suppressor (NF1), genes encoding the succinate dehy-
drogenase (SDH) complex subunits, TMEM127, and 
MYC-associated factor X (MAX) [7]. Neumann et al. [5] 
suggested that routine analysis for mutations of the RET, 
VHL, SDHD, and SDHB genes in patients with apparently 
sporadic presentation of pheochromocytoma should 
be considered as the clinical standard of care. However, 
whether these genetic alterations are also associated with 
composite pheochromocytoma remains unclear.
Kikuchi et al. [8] reported that the histological transfor-
mation from pheochromocytoma to a composite tumor 
might occur over a long clinical course. They suggested 
that age-associated changes to the microenvironment 
might influence the differentiation of pheochromocy-
toma cells into neuronal cells. Therefore, it is possible 
that the changes to the microenvironment caused by 
chronic renal failure influence the pathogenesis of ordi-
nary/composite pheochromocytoma, as with Case 3 in 
the present report. Nevertheless, the precise mechanism 
of histopathological transformation is unclear. Approxi-
mately 71% of composite pheochromocytomas coexist 
with ganglioneuroma. These tumors occur with equal 
frequency in males and females, and most patients are 
aged 40–60 years [9].
Ganglioneuroma is the most common benign tumor 
among neuroblastic tumors and is composed of ganglio-
cytes and mature stroma. In contrast, ganglioneuroblas-
toma is composed of mature gangliocytes and immature 
neuroblasts [3]. It exhibits malignant potential and 
occurs most commonly in infants and young children; 
it presents only rarely after 10  years of age [2]. Com-
posite pheochromocytoma–ganglioneuroblastoma is an 
extremely rare tumor [10, 11], particularly in patients 
undergoing hemodialysis, such as Case 3 in the current 
study. Fujiwara et  al. [10] reviewed seven patients with 
composite pheochromocytoma–ganglioneuroblastoma. 
Two patients died of metastasis from a malignant pheo-
chromocytoma component. Five patients with localized 
tumors underwent complete resection with no adjuvant 
chemotherapy or radiation; all of these patients were 
alive at the time of publication.
In recent years, the estimation of proliferative activities 
using Ki67 immunostaining has become an important 
tool when assessing endocrine tumors. Tavangar et  al. 
[12] indicated that pheochromocytomas with malignant 
behavior usually contain >5% Ki67-positive nuclei. In the 
present cases, the rate of Ki67-positive cells was 6.2, 4.3, 
and 1.0%, respectively, and all patients remained free of 
tumor recurrence for up to 6 years postsurgery without 
adjuvant chemotherapy or radiation. Kimura et  al. [13] 
reported a scoring scale based on six factors: histologi-
cal pattern, cellularity, coagulation necrosis, vascular/
capsular invasion, Ki67 immunoreactivity, and types of 
catecholamine produced. This grading system for adre-
nal pheochromocytoma and extra-adrenal sympathetic 
paraganglioma might be useful for predicting patients’ 
prognosis. However, the clinicopathological indicators 
necessary to accurately predict the prognosis in patients 
with composite pheochromocytoma have not been fully 
established. Therefore, in cases with a high probability of 
malignancy, adequate and accurate postoperative follow-
up is required [14].
Consent
Written informed consent was obtained from all patients 
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